Feldene is a widely registered non-steroidal anti-inflammatory based on piroxicam, with marketing authorisation in 32 countries — a footprint that places it in front of travellers and expatriates across Europe, Latin America, the Asia-Pacific region, and the Mediterranean basin. The page you are reading is intended for the international reader trying to identify Feldene abroad, or recognise it from a familiar context back home.
Piroxicam is prescribed for pain and for a range of inflammatory musculoskeletal conditions, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, spondyloarthritis, and tendinitis. The structured indication section below this introduction lists each registered use in the markets where Feldene is sold, alongside the pharmacological categories the molecule belongs to.
Because Feldene has been on the international market for decades, travellers regularly encounter the same active ingredient under different commercial names — sometimes as Feldene itself, sometimes as a piroxicam-containing generic, and sometimes as a topical preparation for joint and muscular pain rather than an oral product. Markets where Feldene is registered include Brazil, France, Indonesia, Australia, and Egypt, but regulatory packaging, prescription pathways, and available formulations vary considerably between them. A pharmacist in any of these countries can confirm whether a locally stocked piroxicam product corresponds to what the patient was taking elsewhere.
Other molecules within the broader non-steroidal anti-inflammatory class are sold in many of the same markets under their own brand names and are used for overlapping indications, although they are not interchangeable on a like-for-like basis. Anyone taking Feldene, considering it, or trying to match it to a regional equivalent should treat the substitution as a clinical question and bring it to a healthcare provider familiar with their history.
